Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2022

View Archived Issues

Novel TLR4 murine model to study dermal sensitization by nickel salts

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

New hederagenin derivatives display multidrug resistance reversal in tumors

AIMer RNA base editing oligonucleotides edit ACTB transcript in the liver of nonhuman primates

Sichuan Haisco Pharmaceutical patents JAK3 inhibitors

Shanghai Haiju Biotechnology divulges new platinum complexes for cancer

New Mat2A inhibitors synthesized by ScinnoHub Pharmaceutical

Merck & Co. presents new KLKB1 inhibitors

Shanghai Litedd presents new RET inhibitors

LY-3372689, a novel OGA enzyme inhibitor for the treatment of Alzheimer's disease

Discovery of alpha-syn aggregation inhibitors for the treatment of PD

Researchers present [11C]JMJ-81 as a new PET tracer for brain PDE4D quantification

JS-009 cleared to advance into clinic in U.S. for advanced solid tumors

Blockade of PTGDR protects mice from severe SARS-CoV-2 infection

Molecular chaperone maintains proteostasis by clearing protein aggregates in cell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...